3SOF

Sorry..should have made a thread on this one yesterday. Being doing nicely last few days.
Maybe watch for a pullback.

Wednesday, December 06 2006 8:25 AM, EST

Developer of HPV-Based PAP Test Joins CytoCore Medical Advisory Board
Business Wire    "US Press Releases "

CHICAGO--(BUSINESS WIRE)--

Dr. Floyd Taub, pioneering founder and first chief executive officer of Digene Inc., the only company with an FDA-approved DNA-based test to detect cervical cancer-causing viruses (the HPV Test), has joined the Scientific-Medical Advisory Board at CytoCore, Inc. (OTCBB:CYCR), a late-stage bio-scientific research company in the process of bringing a suite of reproductive screening and treatment products to worldwide distribution.

In addition to his groundbreaking work in diagnosis of gynecologic cancers, Dr. Taub's expertise encompasses early NanoDrug(TM) development, clinical trials and distribution of these non-toxic immune system enhancing drugs to treat patients with cancer and a variety of infections. He also has founded and currently works with a number of cutting-edge bio-medical organizations, including FindCure.Org, Inc. and LifeTime Pharmaceuticals Inc.

"Dr. Taub has decades of experience with developing and working with leading edge medical technologies, and then bringing commercially significant projects from early development through to market readiness," said Dr. Augusto Ocana, chief executive officer at CytoCore. "He understands the steps needed for development and testing of products in the most time- and cost-effective ways possible prior to widespread distribution. Dr. Taub's input will be very valuable for our cervical, uterine and endometrial cancer diagnostic products."

Prior to his leadership work in the commercial sector, Dr. Taub was head of a pathology unit in the National Institutes of Health, focusing on immunopathology. Under his direction, the unit analyzed some of the first human monoclonal antibodies. Earlier in his tenure at NIH (late 1970's), while in the Laboratory of Biochemistry of the National Cancer Institute, he devised and implemented the first computerized image processing analysis of array hybridizations. Computerized analysis of array hybridizations today is one of the major tools of genomics.

An Honors Program graduate in Medical Education at Northwestern University Medical School, Dr. Taub studied pathology at the University of Colorado Medical Center, and was awarded the first Surgical Pathology Fellowship at George Washington University Medical Center. Dr. Taub is Board Certified in pathology and licensed to practice medicine in Maryland and California.

Currently in clinical trials, CytoCore anticipates the launch in mid-2007 of worldwide marketing and distribution of a suite of cervical, uterine and endometrial cancer screening and diagnostic tools that will impact women's reproductive healthcare on a global scale.

"I am delighted to be part of the CytoCore team as the unique technology CytoCore has developed will lead to major advances in both diagnostics and therapeutics," said Dr. Taub. "The documented success in both the collection and analysis of gynecologic and urinary track specimens puts CytoCore in a unique position to rapidly bring to market the next set of significant advances in diagnosis and therapy of these cancers."

"I am particularly intrigued with the current EndoScan test and trial," Dr. Taub said. "This test may do for endometrial cancer what the PAP smear and HPV testing has done for cervical cancer. Routine screening for endometrial cancer, which is currently not possible, may become the standard of care. With the high prevalence and concern associated with prescribed hormones this test is especially important. Use in such high risk populations may allow rapid regulatory and market acceptance."




Monday, December 04 2006 8:41 AM, EST

CytoCore Announces Successful Early Testing for Bladder Cancer

Business Wire    "US Press Releases "

CHICAGO--(BUSINESS WIRE)--

CytoCore, Inc. (OTCBB:CYCR), a late-stage bio-scientific research company, today announced highly accurate results in using the P2X7 biomarker to detect bladder cancer -- suggesting much broader implications for its use in the early detection of cancer in all epithelial cells.

Following closely recent test results confirming the efficacy of the P2X7 marker in early identification of endometrial and cervical cancers, this new finding strongly indicates the biomarker's potential effectiveness in early screening for bladder cancer, in confirming the presence of bladder cancer in diagnostically difficult cases and perhaps in predicting the biologic potential of an individual tumor in terms of recurrence and progression to more advanced disease.

"One of the challenges in the field is to predict the malignant potential of an individual bladder neoplasm, since the pathologist's estimate of this parameter, in conjunction with other clinical criteria, strongly influences patient management," said Dr. Greg MacLennan, associate professor of pathology and director of the Tissue Procurement and Histology Core Facility at the Case Comprehensive Cancer Center, CASE (Case Western Reserve) University. "If the utility of P2X7 in bladder lesions is as good as in endometrial lesions, it has tremendous potential for use in the fields of urology and oncology."

Dr. MacLennan, who is collaborating with CytoCore, further added, "We are currently investigating whether the P2X7 biomarker can also differentiate borderline and precancerous lesions of the bladder, as was found to be the case in our studies of borderline and precancerous lesions of the uterine cervix and endometrium."

Dr. George Gorodeski, director of CytoCore's Scientific Advisory Board, explained that the P2X7 protein and mRNA had shown the ability to differentiate normal and cancer tissues both in uterine and urinary samples. "The reason could be that epithelia of the reproductive and urinary tracts arise from common embryonic sites and therefore may share common biological behavior and susceptibilities for the development of cancer. Statistical evaluation of the data revealed sensitivity and specificity rates of greater than 96 percent," stated Dr. Gorodeski.

These results confirm similar data, published recently in the American Association Cancer Research journal "Cancer Epidemiology Biomarkers & Prevention," that found the P2X7 biomarker highly effective in identifying endometrial and cervical cancers in women (see link at: http://cebp.aacrjournals.org/cgi/content/abstract/15/10/1906).

"Our findings, based on surgical tissue specimens taken from bladder cancer patients, are supported by the biology of the P2X7 marker, which is an apoptotic factor and suggests a causative relationship with cancer development," Dr. Gorodeski said. "We are further involved with validating these results and we plan to test an assay for early bladder detection in upcoming clinical trials."

CytoCore is currently in clinical trials and development with a range of screening, diagnostic and treatment products related to the P2X7 marker and its efficacy in the identification of pervasive reproductive cancers.

    For further information, visit www.CytoCoreInc.com

    About CytoCore Inc.

CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com

Dr. George Gorodeski has a significant financial interest in this research consisting of equity and salary as consultant and Director of the Scientific Advisory Board of CytoCore. Dr. Gorodeski's invention licensed to CytoCore may generate royalty income for Dr. Gorodeski, for University Hospitals of Cleveland, and for CASE University.

CYCR looking good....had a very nice eod run, hit and broke the g-spot

I got in at .43...hoping to see that breakout in the new year.

glta and HAPPY NEW YEAR!!!!!

thanks

julia

Nice pick Julia... applause

Gmarc: I am new to this site.  Just trying to find my way around.  I stumbled upon it while doing a blog search on CYCR.  In since 12/04/06 @ $0.19.  I found it because of the board addition of Clint Severson from Abaxis.  I researched this company as best I could.  A lot of fundamental reasons not to like them but future prospects looked exciting.  I did not think Clint would become involved with any company where he did not believe the positives outweighed any negative concerns.  Clint has an excellent reputation. 

After that Dr. Floyd Taub joined and this added more credibility to the company. 

We should see at least one other member added in the near term, a female.

Some accomplishments in debt reduction and other fundamentals lately have also impressed.

Today's move was a nice way to end this year and set the tone for exciting times next year.  Product launch early 2007 should really give this one some momentum.  I took my original position with risk money and an intent to hold for some time.  Cleared my investment on the double shortly after I bought in.  However, I regretted letting some of those shares go so I added back on the pullback.

I wish us both well on this one and glad to find someone else who has recognized a potential speculative gem. 

Thanks Terliso

Jjkool, thanks for the info. I'm not looking to hold this long term however, the shorter the better actually...so, im hoping it will pop allllll weeeek long..then bye bye CYCR...and on to the next!....lol. But, I do appreciate the good info, never can hurt. I just liked the chart and the break...so lets see where this sucker can take us. But, I sure do wish u well on the long term of this stock and hope the pps hits some nice multiple $ numbers for you.

happy new year

thanks and glta

julia

Up nicely on no news.  Shouldn't have let this one drop off the radar...

Quote from: gmarc66 on December 29, 2006, 04:44:28 PM
CYCR looking good....had a very nice eod run, hit and broke the g-spot

I got in at .43...hoping to see that breakout in the new year.

glta and HAPPY NEW YEAR!!!!!

thanks

julia

Julia, very nice indeed !
Looks like this one paid off for you
Nice work on the pick......Applaud !

52wk Range: 0.08 - 0.53
Volume: 3,073,863
Avg Vol (3m): 601,744
Market Cap: 148.67M

Technicals
Record Price High

Last Price Quote is:
24.14%above 13-day MA
56.20%above 50-day MA

Yup...i sold this too early also, i think i just broke even on it...was taking too long..i have no patience.

turned out nicely though.

glta

julia

The fire continues to blaze...

on fire 

Julia,
whats your opinion about CYCR?

tia
Oliver